Alpha glyceryl

Alpha-GPC (L-Alpha-Glycerylphosphorylcholine / Choline Alfoscerate): A Comprehensive Reference

1. Identity: Names, Chemistry, and Natural Source

Chemical Identity and Synonyms

Alpha-GPC, chemically known as L-alpha-glycerylphosphorylcholine or choline alfoscerate, is a choline-containing phospholipid compound that serves as a precursor to acetylcholine, a key neurotransmitter involved in memory and learning. Its chemical formula is C₈H₂₀NO₆P, with a molar mass of 257.22 g/mol, and it is registered under CAS number 28319-77-9.

Structurally, Alpha-GPC is a choline molecule bound to a glycerol molecule via a phosphate group — or equivalently, it is phosphatidylcholine (a lecithin molecule) without its two fatty acids. It is a choline-containing compound widely found in nature, predominantly in its L configuration, and is considered one of the most utilized sources of choline, due to its high choline content of approximately 41% by weight and its ability to cross the blood–brain barrier.

Common synonyms and trade designations include:

• L-alpha-glycerylphosphorylcholine, choline alfoscerate, glycerylphosphorylcholine, alpha glycerophosphocholine; commercial brand names include AlphaSize® and Somazina®.
• A-GPC is also characterized as a semi-synthetic derivative of lecithin and an esterified form of choline.

Natural Sources and Endogenous Occurrence

Alpha-glycerylphosphorylcholine is a naturally occurring compound found in various food sources, including red meat, wheat, milk, and beans, although it is often not present at adequate levels to achieve the concentrations used in research. Alpha-GPC is found endogenously in certain foods, primarily in trace quantities, with organ meats, eggs, and some dairy products containing trace amounts.

Dietary concentrations are far below supplemental doses. Getting a standard supplemental dose from food alone would require eating over 6 kilograms of dried trout or more than 15 kilograms of beef liver daily, meaning dietary intake is a fraction of therapeutic doses. Alpha-GPC is naturally present in almost every cell membrane in the body.

Commercial Production and Dosage Forms

Most alpha-GPC supplements are synthetically produced in the laboratory through enzymatic reactions using egg or soy lecithin as raw material, and laboratory-produced alpha-GPC supplements are referred to as semisynthetic derivatives of lecithin. Commercial alpha-GPC supplements are produced through two main methods: the traditional approach extracts and hydrolyzes lecithin from soybeans or other phosphatidylcholine-rich plants, isolating alpha-GPC from a natural starting material through chemical or enzymatic processing. The second method is full chemical synthesis, which has become more common because extraction from plants is expensive and yields are low.

Commercial L-alpha-GPC is produced by enzymatic or chemical hydrolysis of phosphatidylcholine followed by purification and crystallization to yield the L-isomer under Good Manufacturing Practice (GMP). Alpha-GPC is available commercially in oral capsule, tablet, and powder forms, as well as in injectable preparations used in clinical settings in some countries. The supplement is produced through a sophisticated extraction and purification process that concentrates the active compound to typically 50% or higher purity levels.

2. Historical and Pharmaceutical Development

Discovery and Early Research

The compound was first prepared in 1948 by Erich Baer and Morris Kates, who published their findings in the Journal of the American Chemical Society under the title "L-α-Glycerylphosphorylcholine." Alpha-GPC was biochemically identified in the mid-20th century (circa 1950) and entered pharmaceutical and clinical research from the 1960s onward; the 1950s saw biochemical identification of glycerophosphocholine derivatives in membranes, while the 1960s–1970s saw animal pharmacology showing brain choline increases and early clinical exploration.

Developed and initially marketed in Italy starting in the late 1980s by Italfarmaco for cerebral cognitive disorders, Alpha-GPC gained prominence through clinical studies in the 1990s, many conducted in Italy, demonstrating its role in improving cognitive and functional outcomes in patients with mild to moderate dementia. In the 1980s–1990s, there was clinical use in parts of Europe and Asia for cognitive impairment and stroke recovery, alongside mechanistic studies clarifying choline donation and membrane synthesis roles.

Traditional Use Context

Alpha-GPC does not have an ancient ethnobotanical or traditional herbal medicine history in the way that plant-derived botanicals do. Alpha-GPC does not have an ancient traditional use separate from dietary choline/phospholipid consumption. Its use is entirely a product of twentieth-century biochemical science and pharmaceutical development. Despite its 1985 marketing authorization in certain countries, there are still discrepancies between countries regarding its approval as a prescription medicine and ongoing discussions about its effectiveness.

Regulatory Status

Alpha-GPC is utilized as a dietary supplement in many countries, while in certain European countries it is a prescription drug used to support treatment of cognitive decline in conditions like Alzheimer's disease and vascular dementia. Although the US Food and Drug Administration (FDA) considers alpha-GPC as generally recognized as safe (GRAS) at dietary intake levels, many countries do not approve its use as a prescription drug, mostly due to the lack of robust evidence on efficacy and safety. The compound is approved as a dietary supplement component under provisions of the Dietary Supplement Health and Education Act of 1994 (DSHEA) and is classified as generally recognized as safe (GRAS) according to FDA standards.

3. Key Constituents, Biochemistry, and Mechanisms of Action

Chemical Structure and Composition

Alpha-GPC is the L-isomer of glycerylphosphorylcholine, a zwitterionic molecule comprising a glycerol backbone, a phosphate ester, and a quaternary trimethylammonium choline headgroup. 100 mg of alpha-GPC contains about 40 mg of choline.

Pharmacokinetics: Absorption and Distribution

When ingested, choline alfoscerate is rapidly absorbed by the gastrointestinal tract and crosses the blood-brain barrier efficiently, which is crucial for a compound that exerts its primary effects within the central nervous system (CNS). It is assumed that alpha-GPC is hydrolyzed by phosphodiesterases in the gut mucosa. After alpha-GPC ingestion, it is metabolically transformed into its active form — choline and glycerophosphate — primarily within the gastrointestinal tract and brain.

Typical oral time to maximum concentration (Tmax) is 0.5–2 hours, and plasma half-life for choline elevation is reported at approximately 4–8 hours. Both labelled compounds in pharmacokinetic studies gave a wide distribution of radioactivity, particularly concentrated in the liver, kidney, lung, and spleen compared to blood. Choline was incorporated into brain phospholipids in increasing amounts within 24 hours of dosing.

Primary Mechanisms of Action

1. Acetylcholine precursor activity: When taken by mouth, alpha-GPC can enter the brain and increase the levels of choline and acetylcholine; higher levels of acetylcholine can increase a type of communication in the brain called cholinergic activity. Once ingested, alpha-GPC is converted to phosphorylcholine and can then serve as a source of choline for acetylcholine (ACh) synthesis.

2. Membrane phospholipid synthesis: Alpha-GPC contributes to anabolic processes responsible for membrane phospholipid and glycerol-lipid synthesis, which positively influence membrane fluidity. From a biochemical perspective, Alpha-GPC serves as both a choline donor and a precursor to phosphatidylcholine, an essential component of cell membranes.

3. Monoaminergic effects: Alpha-GPC is a precursor of acetylcholine and can increase acetylcholine concentration in the brain, and also has a role in cholinergic function as well as monoaminergic transmission, including dopaminergic and serotonergic systems — monoaminergic systems related to feelings and emotions including motivation, reward processing, anxiety, and depression.

4. Growth hormone secretagogue activity: Acetylcholine is not only a neurotransmitter, but also responsible for the action potential that stimulates a muscle to contract, and thus a role for augmenting performance associated with intense muscle contraction both for enhanced power and strength has been suggested for alpha-GPC.

5. Anti-amnesic and neuroprotective effects: Pre-clinical studies have shown that alpha-GPC has an anti-amnesic effect against scopolamine-induced amnesia and a neuroprotective effect in animal models of cerebrovascular disease; it also ameliorates seizure-induced cognitive impairment by reducing neuronal cell death and blood–brain barrier disruption.

6. TMAO-mediated cardiovascular pathway (adverse): Choline, a metabolite of alpha-GPC, has potential adverse effects, and a growing body of evidence suggests that a high plasma choline level is associated with a high risk of cardiovascular disease via trimethylamine-N-oxide (TMAO) produced by gut microbiota from choline, with some studies suggesting that TMAO is also associated with stroke as well as cardiovascular disease.

4. Scientific Evidence by Area of Use

4.1 Cognitive Decline, Dementia, and Alzheimer's Disease

Evidence strength: Moderate for clinical populations with cognitive impairment; weak-to-moderate for healthy adults.

Choline alphoscerate is a choline-containing phospholipid used as a medicine or nutraceutical to improve cognitive function impairment occurring in neurological conditions including adult-onset dementia disorders. Alpha-GPC may improve cognition in patients with dementia, though it is still uncertain whether it has additional benefits over approved drugs; identified studies include one open-label study in patients with mild cognitive impairment, two randomized controlled trials in patients with mild to moderate Alzheimer's disease or dementia, and one review of previous trials in patients with dementia or cerebrovascular disease.

A pivotal individual trial: The largest single trial, by Moreno (2003), gave 261 patients with mild to moderate Alzheimer's disease either 1,200 mg alpha-GPC daily or placebo for 180 days. This multicenter, double-blind, randomized, placebo-controlled trial demonstrated cognitive improvement in the treated group.

Systematic review and meta-analysis findings: A 2023 systematic review and meta-analysis pooled data from seven randomized controlled trials and one prospective cohort study covering 861 participants with adult-onset dementia disorders. The results of this analysis were consistent with those of a previous review, which concluded that alpha-GPC improved cognitive performance in patients suffering from dementia disorders of neurodegenerative or vascular origin, either in combination with cholinesterase inhibitors (ChEIs) or alone.

Comparison with citicoline: Alpha-GPC provides greater and more sustained cognitive benefits than citicoline, supporting its potential role as a more effective therapeutic option for dementia and cognitive dysfunction, including early-stage cognitive decline. An open clinical trial compared 1 g/day alpha-GPC with 1 g/day cytosine diphosphocholine (CDP), both given intramuscularly for 90 days in 120 patients with mild to moderate vascular dementia; both treatments produced definite symptomatic improvement, with results suggesting that in most tests alpha-GPC possessed statistically higher efficacy compared with CDP.

Combination with donepezil: The only double-blind multicenter trial of alpha-GPC reported that active treatment using the acetylcholinesterase inhibitor donepezil and alpha-GPC might slow progressive cognitive decline compared with donepezil treatment alone among 113 participants with Alzheimer disease with cerebrovascular injury after a 12- and 24-month observation period. Different randomized controlled trials (RCTs) involving patients with Alzheimer's disease have shown that the combination of alpha-GPC and donepezil significantly reduces symptoms of depression and apathy compared to treatment with donepezil alone.

Limitations: In a number of clinical studies, alpha-GPC demonstrated benefit in patients with cognitive dysfunction, but it is desirable to reconsider alpha-GPC in larger carefully controlled studies not only as monotherapy but also in association with cholinesterase inhibitor drugs, in light of the limited therapeutic results obtained by the use of cholinesterase inhibitors alone. The discrepancies in approving alpha-GPC as a prescription drug between countries appear to suggest that there may be a lack of sufficient evidence on its efficacy, safety, or both.

4.2 Dementia Conversion Risk: Longitudinal Observational Evidence

Evidence strength: Observational/epidemiological only; cannot establish causation.

In a time-dependent Cox analysis from a large Korean longitudinal study, alpha-GPC users had a lower risk of conversion to AD dementia (hazard ratio [HR] = 0.899, 95% confidence interval [CI]: 0.882–0.918) and to vascular dementia (HR = 0.832, 95% CI: 0.801–0.865), adjusting for age, sex, and chronic diseases. Even among participants analyzed through 1:1 propensity score matching (PSM) considering age, sex, income level, chronic diseases, smoking, drinking, and physical activity, alpha-GPC users exhibited a lower risk of AD dementia (HR = 0.938, 95% CI: 0.896–0.981) and VaD (HR = 0.767, 95% CI: 0.708–0.830). These findings are observational and subject to confounding; they cannot establish that alpha-GPC prevented dementia conversion.

4.3 Cognitive Function in Healthy Adults

Evidence strength: Preliminary; small samples, short durations, mixed results.

Due to alpha-GPC's ability to increase choline levels, as well as evidence that disruption in cholinergic transmission leads to learning and memory deficits, interest in alpha-GPC supplementation to support cognition has been evident for several years; research findings are currently mixed regarding alpha-GPC's potential to impact cognition. When investigated in clinically compromised or healthy aged populations, alpha-GPC studies have indicated that it enhances memory and cognitive function.

One 2024 randomized, double-blind, placebo-controlled, crossover study: Using a randomized, double-blind, placebo-controlled, crossover approach, 20 resistance-trained males (mean age 31.3 ± 11.0 years) consumed either a placebo, 630 mg alpha-GPC (high dose), or 315 mg alpha-GPC (low dose). Both the high-dose and low-dose alpha-GPC supplementation significantly increased cognitive performance as measured by changes in the Stroop Total Score and completion time of the Stroop test. The authors noted a conflict of interest (sponsor affiliation), which is a relevant limitation.

Scopolamine-reversal studies: In one controlled study, 32 healthy volunteers received either alpha-GPC or a placebo as pretreatment; ten days later they were injected with scopolamine to induce amnesia. Researchers found that alpha-GPC was able to prevent the impairment of attention and memory normally caused by scopolamine.

Alpha-GPC supplementation has been found to improve reaction time for psychomotor vigilance, Stroop, and serial-subtraction tests at dosages ranging from 200 to 630 mg, whereas at a dosage of 500 mg it resulted in no difference in reaction time, visual and verbal memory during an ImPACT test.

4.4 Motivation and Mood

Evidence strength: Preliminary; one small single-blind study.

In a study from RIKEN Center for Biosystems Dynamics Research, 39 volunteers participated in a single-blind, placebo-controlled design; participants completed a KOKORO scale test to quantify self-reported emotional states three times each day for two weeks preceding treatment and then for a further two weeks while self-administering treatment. Alpha-GPC treatment showed a tendency to increase motivation during the intervention period. Findings reported increased self-reported motivation, yet no difference in depression, anxiety, and mood with the ingestion of 400 mg alpha-GPC.

The study was only single-blind, and the KOKORO scale is a subjective self-report tool, limiting the strength of these conclusions.

4.5 Athletic Performance and Growth Hormone Secretion

Evidence strength: Preliminary to moderate; small trials, inconsistent results.

Using a randomized, placebo-controlled, crossover design, seven men with at least two years of resistance training experience ingested 600 mg alpha-GPC or a placebo 90 minutes prior to completing 6 sets × 10 repetitions of Smith Machine squats at 70% of their predetermined 1-repetition maximum; subjects then performed three sets of bench press throws at 50% of their predetermined 1-repetition maximum to assess peak force, peak power, and rate of force development. The data indicate that a single 600 mg dose of alpha-GPC (as AlphaSize™), when administered 90 minutes prior to resistance exercise, increases post-exercise serum growth hormone and peak bench press force.

In another study, serum free choline was found to be elevated in the two alpha-GPC groups as compared to placebo (132% and 59%, respectively); serum TSH was found to be significantly depressed in the 500 mg alpha-GPC group; and group differences were noted for maximum velocity and maximum mechanical power on the countermovement jump (CMJ) with the 250 mg alpha-GPC group demonstrating the greatest improvements.

Previous findings have reported benefits of alpha-GPC supplementation to increase isometric strength and peak force with a 600 mg dosage; however, other studies found contrasting evidence reporting no effect in power, average force, and work capacity. It is possible that findings on alpha-GPC have been inconsistent due to the wide range of dosages administered in each study, ranging from 200 mg to 1 g, and their differences in concentration (50–99%), combination with other substances, and exercise protocol.

Growth hormone studies: A study by Kawamura et al. (2012) showed that a single 1,000 mg dose significantly increased growth hormone secretion at 60 minutes post-ingestion. A smaller study found 600 mg taken before exercise produced a 44-fold increase in GH response compared to 2.6-fold for placebo, along with a 14% increase in peak bench press force; these are intriguing numbers, but the studies are small.

4.6 Post-Stroke Recovery and Cerebrovascular Disorders

Evidence strength: Preliminary; mostly older European trials, limited by methodological quality.

Clinical and preclinical research have explored alpha-GPC for age-related cognitive decline, post-stroke recovery, traumatic brain injury models, and acute ergogenic effects in athletes. Alpha-GPC supplements exhibited a protective role in the brain from injury of vascular origin, based on microanatomy of hippocampus of alpha-GPC-treated biospecimens. Alpha-GPC has also been proposed to offer treatment support for traumatic brain and other cerebrovascular accidents. These claims rest primarily on preclinical and older, smaller clinical studies; high-quality recent RCTs in this indication are lacking.

5. Body Systems and Health Areas of Association

• Central Nervous System / Neurocognition: Choline is an important nutrient essential for proper functioning of liver, muscle, and brain; it is a main constituent of cell and organelle membranes and plays a vital role in numerous physiological processes including signal transduction, DNA and histone methylation, and nerve myelination.
• Peripheral Neuromuscular System: Acetylcholine is responsible for the action potential that stimulates a muscle to contract, and thus alpha-GPC may augment performance associated with intense muscle contraction for enhanced power and strength.
• Endocrine System (Growth Hormone Axis): Alpha-GPC has been shown in small trials to stimulate growth hormone secretion following exercise, an effect attributed to its cholinergic activity modulating pituitary GH release.
• Cardiovascular System (Safety Signal): Concerns have been raised about the potential of alpha-GPC to increase the risk of cardiovascular disease because it serves as a substrate for the synthesis of trimethylamine-N-oxide (TMAO) in the gut, and TMAO is associated with adverse cardiovascular outcomes.
• Cell Membrane Integrity: Alpha-GPC serves as both a choline donor and a precursor to phosphatidylcholine, an essential component of cell membranes.

6. Dosage Forms and Reported Dosages

Alpha-GPC is available in oral capsules, powders, and tablets, as well as in parenteral (injectable) formulations used pharmaceutically in some countries. For attenuating symptoms of cognitive decline, almost all studies used a dosage of 1,200 mg per day, divided into three doses of 400 mg. For boosting power output, studies have used a dosage of 300–600 mg, supplemented 30–60 minutes prior to exercise.

Specific dosages reported in individual studies:

• In Alzheimer's trials, patients have taken 400 mg three times per day (1,200 mg total).
• In one motivation study, participants were administered capsules containing 200 mg of alpha-GPC, self-administering two capsules once daily at bedtime for 2 weeks, for a total daily dose of 400 mg.
• Cognitive performance studies have used doses of 315 mg (low dose) and 630 mg (high dose), administered acutely.
• A single 600 mg dose administered 90 minutes prior to resistance exercise has been used in athletic performance studies.
• A single 1,000 mg dose has been used in a growth hormone secretion study.
• A dose of 1 g/day administered intramuscularly for 90 days was used in a vascular dementia comparison trial.
• Reaction time studies have used dosages ranging from 200 to 630 mg.

It should be noted that alpha-GPC is typically formulated at 50% or 99% purity concentrations, which means the labeled dose may represent a mixture rather than pure alpha-GPC. This variability contributes to the inconsistency of findings across studies.

7. Safety Considerations and Drug Interactions

Common Reported Adverse Effects

Common side effects reported in clinical use may include constipation, nausea, or an upset stomach. As a metabolite, choline itself can produce potential adverse effects such as fishy body odor, vomiting, excessive sweating and salivation, hypotension, and liver diseases at high levels.

Stroke Risk: The 2021 Korean Cohort Study

A significant safety signal emerged from a large population-based study. A population-based, retrospective cohort study was conducted using data from the National Health Insurance Service of South Korea, including men and women aged 50 years or older without underlying stroke or Alzheimer disease (N = 12,008,977); all participants were divided into whether they were prescribed alpha-GPC during 2006–2008. After matching for all covariates, alpha-GPC users had a higher risk for total stroke (adjusted HR, 1.43; 95% CI, 1.41–1.46), ischemic stroke (aHR, 1.34; 95% CI, 1.31–1.37), and hemorrhagic stroke (aHR, 1.37; 95% CI, 1.29–1.46). In this cohort study, use of alpha-GPC was associated with a higher 10-year incident stroke risk in a dose-response manner after adjusting for traditional cerebrovascular risk factors.

Important limitations and context for this finding: The authors noted that the study could be influenced by confounding variables, as alpha-GPC is often prescribed to individuals with preexisting health risks. The Korean cohort study is observational, not a randomized trial, and confounding factors may contribute to the signal; alpha-GPC is prescribed in South Korea for cognitive impairment, meaning users may have been sicker at baseline than non-users despite statistical matching. A later systematic review and meta-analysis criticized the statistical analysis of the South Korean cohort study, describing it as questionable and imprecise.

TMAO and Atherosclerosis Mechanism

In order to test whether polymicrobial communities possessed the capacity to metabolize GPC to TMA (the precursor for TMAO), researchers incubated different murine intestinal segments with deuterium-labeled GPC under anaerobic conditions; production of labeled TMA was observed from the ileum, cecum, and colon, but not from the duodenum or jejunum, consistent with TMA-producing bacteria being enriched in the more distal intestine. A 2021 mouse study found that alpha-GPC supplementation promoted atherosclerosis. However, the currently available evidence is preliminary in nature.

In healthy people this may not be something to worry about, but in people with a high risk of cardiovascular disease it may be prudent to consider the added risk.

Drug Interactions

The only formally reported drug interaction for alpha-GPC is scopolamine, a drug used for motion sickness. Alpha-GPC increases a chemical in the brain called acetylcholine; scopolamine blocks this same chemical; however, it is not known if alpha-GPC decreases the benefits of scopolamine.

Broader pharmacodynamic interaction categories: Potentially interacting medications include anticholinergic medicines, which include antihistamines and medicines commonly used for overactive bladder, Parkinson's disease, or stomach problems; the interactions between alpha-GPC and medicines are not fully understood, and research on drug interactions is incomplete.

Alpha-GPC increases acetylcholine, which may reduce the effectiveness of anticholinergic drugs used for conditions like overactive bladder or Parkinson's disease; taking them together could interfere with intended treatment outcomes. Cholinesterase inhibitors (like donepezil for Alzheimer's) also boost acetylcholine; combined use may amplify effects, potentially causing dizziness, nausea, or muscle weakness.

Regulatory and Evidence Caveats

The FDA has not formally reviewed alpha-GPC for safety and effectiveness as a drug. The discrepancies of approving alpha-GPC as a prescription drug between countries appear to suggest that there may be a lack of sufficient evidence on its efficacy, safety, or both. Most of the foundational clinical trials were conducted in Italy in the 1990s and vary in methodological quality. Larger, longer-term, independently funded randomized controlled trials are needed to confirm both efficacy claims across indications and to definitively characterize the cardiovascular safety signal.

References

• Sagaro GG, Traini E, Amenta F. Activity of Choline Alphoscerate on Adult-Onset Cognitive Dysfunctions: A Systematic Review and Meta-Analysis. Journal of Alzheimer's Disease. 2023;92(1):59–70. PMC10041421
• Association of L-α Glycerylphosphorylcholine With Subsequent Stroke Risk After 10 Years. JAMA Network Open. 2021. PMC8613599
• Acute Alpha-Glycerylphosphorylcholine Supplementation Enhances Cognitive Performance in Healthy Men. Nutrients. 2024;16(23):4240. PMC11644786
• Tamura Y, Takata K, Matsubara K, Kataoka Y. Alpha-Glycerylphosphorylcholine Increases Motivation in Healthy Volunteers: A Single-Blind, Randomized, Placebo-Controlled Human Study. Nutrients. 2021;13(6):2091. PMC8235064
• Bellar D, LeBlanc NR, Campbell B. Evaluation of the Effects of Two Doses of Alpha Glycerylphosphorylcholine on Physical and Psychomotor Performance. PMC5629791
• The Nutritional Supplement L-Alpha Glycerylphosphorylcholine Promotes Atherosclerosis. Int J Mol Sci. 2021;22(24):13477. PMC8708068
• Kansakar U, et al. Choline Supplements: An Update. Frontiers in Endocrinology. 2023;14:1148166. PMC10025538
• Association between L-α glycerylphosphorylcholine use and delayed dementia conversion: A nationwide longitudinal study in South Korea. PMC12184023
• Di Perri R, et al. A multicentre trial to evaluate the efficacy and tolerability of alpha-glycerylphosphorylcholine versus cytosine diphosphocholine in patients with vascular dementia. J Int Med Res. 1991;19:330–41. PMID 1916007
• Traini E, et al. Revisiting choline alphoscerate profile: a new, perspective, role in dementia? Curr Alzheimer Res. 2013. PMID 23387341
• Abbiati G, et al. Absorption, tissue distribution and excretion of radiolabelled compounds in rats after administration of [14C]-L-alpha-glycerylphosphorylcholine. Eur J Drug Metab Pharmacokinet. 1993;18(2):173–80. PMID 8243501
• Ziegenfuss TN, et al. Acute supplementation with alpha-glycerylphosphorylcholine augments growth hormone response to, and peak force production during, resistance exercise. Journal of the International Society of Sports Nutrition. 2008;5(Suppl 1):P15
• Alzheimer's Drug Discovery Foundation — Cognitive Vitality: Alpha-GPC (Choline Alfoscerate) & Your Brain
• Examine.com — Alpha-GPC: Benefits, Dosage, and Side Effects
• Li J, et al. L-Alpha-Glycerylphosphorylcholine (L-α-GPC): A Comprehensive Review of Its Preparation Techniques and Versatile Biological Effects. Journal of Food Science. 2025;90:e70338
• PubChem — L-alpha-Glycerylphosphorylcholine (GPC) | C8H20NO6P | CID 71920
• Comparison of the effects of choline alphoscerate and citicoline in patients with dementia disorders: a systematic review and meta-analysis. Frontiers in Neurology. 2025
• News-Medical.net — Alpha-GPC: What Science Says About Its Role in Brain Health
• The Nutritional Supplement L-Alpha Glycerylphosphorylcholine Promotes Atherosclerosis. Int J Mol Sci. 2021;22(24):13477